Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Troels BrynskovInger Christine MunchTobias Malte LarsenLiv ErngaardTorben Lykke SørensenPublished in: Acta ophthalmologica (2019)
A treatment-as-needed regimen stabilized BCVA in active nAMD up to 10 years in most eyes. Baseline BCVA was the most important prognostic factor.